Novo Nordisk shares fell as much as 7% on Monday after the company unveiled its new growth strategy aimed at reviving its position in the rapidly expanding obesity drug market. The Danish pharmaceutical giant announced plans to launch more than five drugs with 'multi-blockbuster' potential by 2030 and set a pipeline sales target of over 150 billion Danish kroner ($23 billion) by 2035 [1]. Despite these ambitious goals, the Copenhagen-listed shares dropped sharply, with a 7% decline in morning trading and a 5% decrease later in the day [1].
At the company's Capital Markets Day in London, CEO Mike Doustdar addressed investor concerns about the looming loss of patent exclusivity for semaglutide, the active ingredient in Novo Nordisk's flagship weight-loss and diabetes drugs Wegovy and Ozempic. The patent is scheduled to expire in 2032 in the U.S., which currently accounts for more than half of Novo Nordisk's sales [1]. Doustdar acknowledged the competitive threat posed by other pharmaceutical companies entering the market and emphasized the need for Novo Nordisk to be prepared for increased competition and price pressure [1].
Doustdar also outlined plans to diversify the company's portfolio, stating that Novo Nordisk does not 'belittle' the challenges associated with the loss of exclusivity. He expressed confidence that the company would emerge from this period as a larger and more diversified entity [1]. Additionally, Novo Nordisk expects its revenue growth between 2026 and 2030 to be in line with industry peers, signaling a commitment to maintaining competitiveness despite the anticipated challenges [1].
CONCLUSION
Novo Nordisk's announcement of ambitious sales targets and plans for new blockbuster drugs was overshadowed by investor concerns about the impending loss of patent exclusivity for semaglutide, resulting in a sharp drop in share price. The company aims to diversify and maintain growth, but faces significant competitive and pricing pressures in the coming years. Market sentiment is cautious, reflecting uncertainty about Novo Nordisk's ability to sustain its leadership in the obesity drug market.